Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0031 • ACR Convergence 2020
Metabolomics Profiling Predicts Outcome of Tocilizumab in Rheumatoid Arthritis
Jessica Murillo-Saich¹, Cesar Diaz-Torne², M. Angeles Ortiz², Roxana Coras¹, Arthur Kavanaugh³, Hector Corominas², Silvia Vidal² and Monica Guma⁴, ¹University of California San Diego, La Jolla, CA, ²Institut Rec. Hospital de la Santa Creu I Sant Pau., Barcelona, Spain, ³Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ⁴Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Metabolomics may provide information about the activity and severity of specific diseases and potentially help discriminate between diseases. Choosing the right biological therapy earlier…
Abstract Number: 0103 • ACR Convergence 2020
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
Rachel Elam¹, Sandeepkumar Gupta², Omar Tolaymat², Sowmya Vasan³, Carolyn Crandall⁴, Jean Wactawski-Wende⁵, Karen Johnson⁶ and Laura Carbone², ¹Augusta University, Evans, GA, ²Augusta University, Augusta, GA, ³WHI, Seattle, WA, ⁴UCLA, Los Angeles, CA, ⁵University of Buffalo, Buffalo, NY, ⁶University of Tennessee Health Sciences Center, Memphis, TN
Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of…
Abstract Number: 0148 • ACR Convergence 2020
Perspectives on Treatment Burden for Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Patients: A Qualitative Study
Alexis Ogdie¹, Yomei Shaw², Michele Almonte³, Ervant Maksabedian⁴ and Kaleb Michaud⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, East Lansing, MI, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc., LOS ANGELES, CA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Physicians often consider adverse events when choosing therapies for PsA and RA but may give less attention to other ways in which treatments affect…
Abstract Number: 0185 • ACR Convergence 2020
Prevalence of Migraine and Neuropathic Pain in Rheumatic Disease
Sylvain Mathieu¹, Marion Couderc¹, Bruno Pereira¹, Jean-Jacques Dubost¹, Sandrine Malochet-Guinamand², Anne Tournadre², Martin Soubrier¹ and Xavier Moisset², ¹CHU Gabriel Montpied, Clermont-Ferrand, France, ²CHU Gabriel Montpied, Clermont-Ferrand
Background/Purpose: The aim of our study was to assess the prevalence of migraine and neuropathic pain in a sample of patients with chronic inflammatory rheumatism…
Abstract Number: 0201 • ACR Convergence 2020
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA)
Xiaofeng Zeng¹, Ying Jiang², Ying Yang³ and Hanying Li⁴, ¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ²Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Jiangsu Hengrui Medicine Co., Ltd, Guangzhou, China (People's Republic), ⁴Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic)
Background/Purpose: Proinflammatory cytokine activation of JAK/STAT signal pathway is critical in the pathogenesis and progression of RA. SHR0302, a potent and selective inhibitor of JAK1,…
Abstract Number: 0217 • ACR Convergence 2020
Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results
Rene Westhovens¹, William F. C. Rigby², Désirée van der Heijde³, Daniel W.T. Ching⁴, William Stohl⁵, Jonathan Kay⁶, Arvind Chopra⁷, Beatrix Bartok⁸, Franziska Matzkies⁸, Zhaoyu Yin⁸, Ying Guo⁹, Chantal Tasset¹⁰, John S. Sundy⁸, Angelika Jahreis⁸, Neelufar Mozaffarian¹¹, Osvaldo Daniel Messina¹², Robert Landewé¹³, Tatsuya Atsumi¹⁴ and Gerd Burmester¹⁵, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Timaru Hospital, Timaru, New Zealand, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Center for Rheumatic Diseases, Pune, India, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Gilead Sciences, Inc., Foster City, ¹⁰Galapagos NV, Mechelen, Belgium, ¹¹Ichnos Sciences, Paramus, ¹²IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, ¹³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ¹⁵Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an oral, potent, selective JAK 1 inhibitor. FINCH 3 assessed FIL efficacy and safety in methotrexate (MTX)-naïve patients (pts) with rheumatoid…
Abstract Number: 0234 • ACR Convergence 2020
Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Leonard Calabrese², Filip Van den Bosch³, Kunihiro Yamaoka⁴, Carlo Selmi⁵, Yanna Song⁶, Barbara Hendrickson⁷, Ivan Lagunes-Galindo⁸ and Iain McInnes⁹, ¹Oregon Health & Science University, Portland, OR, ²Cleveland Clinic, Cleveland, OH, ³Ghent University Hospital, Ghent, Belgium, ⁴Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁵Humanitas Research Hospital and Humanitas University, MIlan, Italy, ⁶AbbVie Inc., North Chicago,, IL, ⁷AbbVie, Inc, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA) is a selective and reversible Janus kinase (JAK) inhibitor with an approved dose of 15 mg once daily (QD) for the treatment…
Abstract Number: 0461 • ACR Convergence 2020
High-Throughput Single-Cell Analysis Reveals Unique Lung Cellular Subsets in a Murine Model of Rheumatoid Arthritis-Inflammatory Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Amy Nelson¹, Meng Niu¹, Chittibabu Guda¹, James Eudy¹, Austin Barry¹, Debra Romberger¹, Michael Duryee¹, Bryant England¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA)-associated inflammatory lung disease is an extra-articular manifestation of RA associated with increased morbidity and mortality, whose precise molecular mechanisms remain undetermined.…
Abstract Number: 0546 • ACR Convergence 2020
Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis
Alexis Ogdie¹, Kathleen Bush¹, Michael George¹, Mitesh Patel¹, William Nowell², Kelly Gavigan³, Jeffrey Curtis⁴ and Joshua Baker⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, New York City, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Regular physical activity may have benefits for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but patients with active disease are often reluctant…
Abstract Number: 0743 • ACR Convergence 2020
Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis
William Robinson¹, Chun Wu², Sarah Hu², Sean Connolly² and Sumanta Mukherjee², ¹Stanford University School of Medicine, Stanford, CT, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: ACPAs are sensitive, highly specific markers of RA. Current tests cannot differentiate ACPA+ RA subtypes. Fine-specificity ACPAs (FS) can distinguish between ACPA+ RA subtypes…
Abstract Number: 0760 • ACR Convergence 2020
X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis
Andrea Di Matteo¹, Kulveer Mankia¹, Jacqueline L Nam¹, Edoardo Cipolletta², Leticia Garcia-Montoya³, Laurence Duquenne¹, Emma Rowbotham⁴ and Paul Emery⁵, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi (AN), Italy, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: In individuals at-risk of RA, the identification of reliable biomarkers for the future development of clinical arthritis is of critical importance for risk-stratification and…
Abstract Number: 0777 • ACR Convergence 2020
CLEC12A Expression as a Potential Predictor of Disease Activity in Early Rheumatoid Arthritis
Myriam Vaillancourt¹, Philippe Desaulniers¹, Guillaume Paré¹, Nathalie Pagé¹, Asmaa Lachaab¹, Anthony Kerever¹, Anne-Sophie Julien¹, Nathalie Amiable¹, Martin Pelletier¹, Philippe Tessier¹, Louis Bessette², Paul Fortin³, Laetitia Michou¹ and Maria Fernandes¹, ¹Université Laval, Québec, QC, Canada, ²Laval University, Quebec, Canada, ³CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Rheumatoid arthritis (RA) develops as a result of the dysregulation of immune activating and inhibitory pathways. Several lines of evidence indicate that inhibitory receptors…
Abstract Number: 0794 • ACR Convergence 2020
Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly
Aina Teniente-Serra¹, Lourdes Mateo², Agueda Prior³, Monica Guma⁴, Eva Martinez-Caceres¹ and Melania Martinez-Morillo⁵, ¹Department of Immunology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain
Background/Purpose: Multiple lymphocyte subsets like T and B cells have been connected to joint infiltration and inflammation in rheumatoid arthritis (RA). Identification of leucocyte subsets…
Abstract Number: 0810 • ACR Convergence 2020
Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data
Kieran Murray¹, Matthew Turk², Yousef Alammari², Francis Young³, Phil Gallagher⁴, Tajvur Saber⁵, Sinead Maguire⁶, Finbar O'Shea⁶, Ursula Fearon⁷ and Douglas Veale⁸, ¹Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin 4, Ireland, ³Saint Vincent's University Hospital, Dublin 4, ⁴St Vincents University Hospital, UCD, Dublin, Ireland, ⁵Peshawar Rheumatology Clinic, Dabgari Garden, Northern Areas, Pakistan, ⁶St James' Hospital, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁸EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Biologic therapies are widely used and greatly improve outcomes in RA and PsA. Yet, our ability to predict long-term remission and persistence remains limited.…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].